retatrutide weight loss retatrutide clinical trial status Retatrutide, an experimental weight-loss drug, has not been approved by the New Weight Loss Drug Retatrutide:

has acted as a consultant of Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk and Sanofi and received speaking fees from Eli Lilly, Novo Nordisk and Sanofi

Keep in mind this time point, as new articles about GLP-1 drugs benefits and risks are being released regularly

It's Marketed as "Herbal" or "All-Natural": These products often use misleading language to suggest they work like prescription GLP-1s without containing the actual medication

But for some reason we've never really seen obesity as a largely preventable public health problem

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (surpass-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 surpass-3 trial